{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:49:34Z","timestamp":1793317774701,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["20ZR1468500"],"award-info":[{"award-number":["20ZR1468500"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bmcl.2025.130283","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:08:28Z","timestamp":1747307308000},"page":"130283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["An overview of PROTACs targeting KRAS and SOS1 as antitumor agents"],"prefix":"10.1016","volume":"125-126","author":[{"given":"Zhiqiu","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bmcl.2025.130283_bb0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"12","key":"10.1016\/j.bmcl.2025.130283_bb0010","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc2960","article-title":"Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?","volume":"10","author":"Vigil","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130283_bb0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.semcdb.2011.09.002","article-title":"Ras trafficking, localization and compartmentalized signalling","volume":"23","author":"Prior","year":"2012","journal-title":"Semin Cell Dev Biol"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130283_bb0020","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol Cancer Res"},{"issue":"18","key":"10.1016\/j.bmcl.2025.130283_bb0025","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1073\/pnas.81.18.5704","article-title":"Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules","volume":"81","author":"Gibbs","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130283_bb0030","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s10555-020-09912-8","article-title":"The effects of mutant Ras proteins on the cell signalome","volume":"39","author":"Tak\u00e1cs","year":"2020","journal-title":"Cancer Metastasis Rev"},{"issue":"14","key":"10.1016\/j.bmcl.2025.130283_bb0035","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.bmcl.2025.130283_bb0040","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130283_bb0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"issue":"7781","key":"10.1016\/j.bmcl.2025.130283_bb0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130283_bb0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"issue":"25","key":"10.1016\/j.bmcl.2025.130283_bb0060","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130283_bb0065","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"issue":"7790","key":"10.1016\/j.bmcl.2025.130283_bb0070","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130283_bb0075","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/2159-8290.CD-20-1616","article-title":"Mechanisms of resistance to KRASG12C-targeted therapy","volume":"11","author":"Akhave","year":"2021","journal-title":"Cancer Discov"},{"issue":"25","key":"10.1016\/j.bmcl.2025.130283_bb0080","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"issue":"7886","key":"10.1016\/j.bmcl.2025.130283_bb0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"issue":"6691","key":"10.1016\/j.bmcl.2025.130283_bb0090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/28548","article-title":"The structural basis of the activation of Ras by Sos","volume":"394","author":"Boriack-Sjodin","year":"1998","journal-title":"Nature"},{"issue":"45","key":"10.1016\/j.bmcl.2025.130283_bb0095","doi-asserted-by":"crossref","first-page":"16692","DOI":"10.1073\/pnas.0608127103","article-title":"A Ras-induced conformational switch in the Ras activator son of sevenless","volume":"103","author":"Freedman","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2025.130283_bb0100","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ncomms2173","article-title":"Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis","volume":"3","author":"Jeng","year":"2012","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130283_bb0105","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/ncb3175","article-title":"RasGRP1 opposes proliferative EGFR\u2013SOS1\u2013Ras signals and restricts intestinal epithelial cell growth","volume":"17","author":"Depeille","year":"2015","journal-title":"Nat Cell Biol"},{"issue":"24","key":"10.1016\/j.bmcl.2025.130283_bb0110","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1182\/blood-2018-09-874107","article-title":"Unique dependence on Sos1 in KrasG12D-induced leukemogenesis","volume":"132","author":"You","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2025.130283_bb0135","doi-asserted-by":"crossref","unstructured":"Gort E, Johnson ML, et al. A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors. J Clin Oncol 2020;38:TPS3651-TPS3651. doi: https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS3651.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3651"},{"issue":"14","key":"10.1016\/j.bmcl.2025.130283_bb0140","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1021\/acs.jmedchem.2c00741","article-title":"Design and discovery of MRTX0902, a potent, selective, brain-penetrant, and orally bioavailable inhibitor of the SOS1:KRAS protein-protein interaction","volume":"65","author":"Ketcham","year":"2022","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130283_bb0145","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACS: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew Chem Int Ed Eng"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130283_bb0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130283_bb0155","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr Opin Chem Biol"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130283_bb0160","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130283_bb0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med Chem Lett"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130283_bb0170","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmcl.2025.130283_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116901","article-title":"Recent advances in dual PROTACs degrader strategies for disease treatment","volume":"279","author":"Liu","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130283_bb0180","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmcl.2025.130283_bb0185","author":"Arvinas Inc"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130283_bb0190","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent Sci"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130283_bb0195","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130283_bb0200","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","article-title":"Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRASG12D","volume":"67","author":"Zhou","year":"2024","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130283_bb0205","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1021\/acs.jmedchem.1c01774","article-title":"Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human cancer cells harboring various KRAS mutations","volume":"65","author":"Zhou","year":"2022","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130283_bb0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chembiol.2019.12.006","article-title":"Exploring targeted degradation strategy for oncogenic KRASG12C","volume":"27","author":"Zeng","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmcl.2025.130283_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114088","article-title":"Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC","volume":"230","author":"Yang","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"24","key":"10.1016\/j.bmcl.2025.130283_bb0220","doi-asserted-by":"crossref","first-page":"16432","DOI":"10.1021\/acs.jmedchem.2c01300","article-title":"Development of SOS1 inhibitor-based degraders to target KRAS-mutant colorectal cancer","volume":"65","author":"Bian","year":"2022","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130283_bb0225","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1021\/acs.jmedchem.3c00075","article-title":"Discovery of a potent, cooperative, and selective SOS1 PROTAC ZZ151 with in vivo antitumor efficacy in KRAS-mutant cancers","volume":"66","author":"Zhou","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130283_bb0230","series-title":"Inhibitors of KRAS G12C. WO2015054572 A1","author":"Li","year":"2015"},{"key":"10.1016\/j.bmcl.2025.130283_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105447","article-title":"Discovery of KRas G12C-IN-3 and pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity","volume":"117","author":"Li","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2025.130283_bb0240","article-title":"Modulators of proteolysis and associated methods of use","volume":"A2","author":"Crew","year":"2019","journal-title":"WO2019195609"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130283_bb0245","doi-asserted-by":"crossref","first-page":"176","DOI":"10.25082\/JPBR.2021.01.002","article-title":"Efficacy and mechanism of KRAS G12C PROTAC in inhibiting the proliferation of pancreatic cancer cells","volume":"3","author":"Gao","year":"2022","journal-title":"J Pharm Biopharm Res"},{"key":"10.1016\/j.bmcl.2025.130283_bb0250","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cbpa.2016.08.011","article-title":"Targeting biomolecules with reversible covalent chemistry","volume":"34","author":"Bandyopadhyay","year":"2016","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.bmcl.2025.130283_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117153","article-title":"Design, synthesis and biological evaluation of KRASG12C-PROTACs","volume":"78","author":"Zhang","year":"2023","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130283_bb0260","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130283_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115857","article-title":"Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-mutation","volume":"261","author":"Yang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130283_bb0270","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0959-8049(22)00881-4","article-title":"ASP3082, a first-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models","volume":"174","author":"Nagashima","year":"2022","journal-title":"Eur J Cancer"},{"issue":"7_Supplement","key":"10.1016\/j.bmcl.2025.130283_bb0275","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1158\/1538-7445.AM2023-5735","article-title":"Abstract 5735: novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models","volume":"83","author":"Nagashima","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130283_bb0285","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.675","article-title":"608O preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)","volume":"35","author":"Park","year":"2024","journal-title":"Ann Oncol"},{"issue":"6715","key":"10.1016\/j.bmcl.2025.130283_bb0290","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"issue":"7968","key":"10.1016\/j.bmcl.2025.130283_bb0295","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130283_bb0300","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1073\/pnas.1315798111","article-title":"Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange","volume":"111","author":"Burns","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"10.1016\/j.bmcl.2025.130283_bb0305","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1021\/acs.jmedchem.8b00360","article-title":"Discovery of aminopiperidine indoles that activate the guanine nucleotide exchange factor SOS1 and modulate RAS signaling","volume":"61","author":"Abbott","year":"2018","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130283_bb0310","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acsmedchemlett.8b00296","article-title":"Discovery of quinazolines that activate SOS1-mediated nucleotide exchange on RAS","volume":"9","author":"Abbott","year":"2018","journal-title":"ACS Med Chem Lett"},{"issue":"19","key":"10.1016\/j.bmcl.2025.130283_bb0315","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.1021\/acs.jmedchem.8b01108","article-title":"Discovery and structure-based optimization of benzimidazole-derived activators of SOS1-mediated nucleotide exchange on RAS","volume":"61","author":"Hodges","year":"2018","journal-title":"J Med Chem"},{"issue":"15","key":"10.1016\/j.bmcl.2025.130283_bb0320","doi-asserted-by":"crossref","first-page":"8325","DOI":"10.1021\/acs.jmedchem.0c00511","article-title":"Discovery of sulfonamide-derived agonists of SOS1-mediated nucleotide exchange on RAS using fragment-based methods","volume":"63","author":"Sarkar","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130283_bb0325","series-title":"Novel benzylamino substituted quinazolines and derivatives as SOS1 inhibitors. WO2018115380 A1","author":"Gmachl","year":"2018"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130283_bb0330","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130283_bb0335","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1021\/acs.jmedchem.3c02135","article-title":"Discovery of potent SOS1 PROTACs with effective antitumor activities against NCI-H358 tumor cells in vitro\/in vivo","volume":"67","author":"Pang","year":"2024","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130283_bb0340","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1021\/acs.jmedchem.3c01598","article-title":"A potent SOS1 PROTAC degrader with synergistic efficacy in combination with KRASG12C inhibitor","volume":"67","author":"Lv","year":"2024","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130283_bb0345","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.1812963116","article-title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction","volume":"116","author":"Hillig","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2025.130283_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117661","article-title":"Discovery of LHF418 as a new potent SOS1 PROTAC degrader","volume":"103","author":"Li","year":"2024","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130283_bb0355","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1535-7163.MCT-23-0513","article-title":"Cereblon-based bifunctional degrader of SOS1, BTX-6654, targets multiple KRAS mutations and inhibits tumor growth","volume":"23","author":"Begovich","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2025.130283_bb0360","series-title":"SOS1 inhibitors. WO2021127429 A1","author":"Marx","year":"2021"},{"key":"10.1016\/j.bmcl.2025.130283_bb0365","series-title":"Bicyclic heterocyclyl compounds and uses thereof. WO2020180770 A1","author":"Cregg","year":"2020"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130283_bb0370","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/acsmedchemlett.2c00490","article-title":"Design, synthesis, and bioevaluation of pyrido[2,3-d]pyrimidin-7-ones as potent SOS1 inhibitors","volume":"14","author":"Liu","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130283_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129780","article-title":"Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor","volume":"107","author":"Wang","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130283_bb0380","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/0008-5472.CAN-24-1093","article-title":"Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL-positive leukemia","volume":"85","author":"Luo","year":"2025","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130283_bb0385","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/21541248.2019.1611168","article-title":"Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells","volume":"12","author":"Sheffels","year":"2021","journal-title":"Small GTPases"},{"issue":"546","key":"10.1016\/j.bmcl.2025.130283_bb0390","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aar8371","article-title":"Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation","volume":"11","author":"Sheffels","year":"2018","journal-title":"Sci Signal"},{"key":"10.1016\/j.bmcl.2025.130283_bb0395","series-title":"Targeting oncogenic K-Ras mutants with a small-molecule degrader through Nedd4\u20131. bioRxiv 2024.04.26.591418","author":"Zeng","year":"2025"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:06:44Z","timestamp":1762344404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25001921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":74,"alternative-id":["S0960894X25001921"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130283","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of PROTACs targeting KRAS and SOS1 as antitumor agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130283"}}